Emerald Mutual Fund Advisers Trust’s Supernus Pharmaceuticals SUPN Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-273,568	Closed	-$9.26M	–	239
2022 Q3	$9.26M	Buy	273,568 +212,873	+351%	+$6.93M	0.59%	69
2022 Q2	$1.75M	Buy	+60,695	New	+$1.74M	0.1%	137
2018 Q1	–	Sell	-457,407	Closed	-$18.2M	–	258
2017 Q4	$18.2M	Sell	457,407 -45,463	-9%	-$1.8M	0.72%	43
2017 Q3	$20.1M	Buy	502,870 +95,610	+23%	+$4.14M	0.84%	34
2017 Q2	$17.6M	Buy	+407,260	New	+$14.5M	0.77%	52

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's SUPN Position: Q4 2022 in Review

Emerald Mutual Fund Advisers Trust sold out of Supernus Pharmaceuticals (SUPN) in Q4 2022, closing a stake of 273,568 shares — an estimated $9.26M sold.

Emerald Mutual Fund Advisers Trust first reported a position in SUPN in Q2 2017 and held it in 5 quarters. The position peaked at $20.1M in Q3 2017. 263 funds tracked by Wall St. Rank hold SUPN as of Q4 2022.

Emerald Mutual Fund Advisers Trust reported no remaining Supernus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Emerald Mutual Fund Advisers Trust sold 273,568 Supernus Pharmaceuticals shares in Q4 2022, an estimated $9.26M.
Emerald Mutual Fund Advisers Trust first reported a position in Supernus Pharmaceuticals in Q2 2017 and held it in 5 quarters.
Emerald Mutual Fund Advisers Trust's Supernus Pharmaceuticals position peaked at $20.1M in Q3 2017.
263 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2022.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q4 2022, filed 3 Feb 2023.